Back to search

Peptide record

TPDB06820

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06820
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb AI4AVP dbAMP 3.0 DRAVP 2.0 APD_complete PD_Hemolysis
standard
No
A 12-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KRIVQRIKDFLR
Physicochemical Analysis
C71H126N24O16
ANCEGHMPSTWY
R
1571.93
12.13
5
1
5
+4
3.98
-0.708
121.67
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
3
R
0
N
1
D
0
C
0
E
1
Q
0
G
0
H
2
I
1
L
2
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 1 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 2 L: 1 K: 2 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
12
C71H126N24O16
1571.93
12.13
+4
3.98
-0.708
Evidence Records 42 records
Evidence 1 Activity

Activity

MIC
Antibacterial
40 µM

Target

Escherichia coli K12

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
The peptide remained active against E. coli K12 (MIC 40 uM) but not S.aureus USA300 in TSB (MRSA-inactive). It also reduced the viability of T. vagin
Evidence 2 Activity

Activity

MIC
Antifungal
40 µM

Target

Escherichia coli K12

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
The peptide remained active against E. coli K12 (MIC 40 uM) but not S.aureus USA300 in TSB (MRSA-inactive). It also reduced the viability of T. vagin
Evidence 3 Activity

Activity

MIC
Antiparasitic
40 µM

Target

Escherichia coli K12

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
The peptide remained active against E. coli K12 (MIC 40 uM) but not S.aureus USA300 in TSB (MRSA-inactive). It also reduced the viability of T. vagin
Evidence 4 Activity

Activity

MIC
Antiviral
40 µM

Target

Escherichia coli K12

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
The peptide remained active against E. coli K12 (MIC 40 uM) but not S.aureus USA300 in TSB (MRSA-inactive). It also reduced the viability of T. vagin
Evidence 5 Activity

Activity

50% cell death
Toxicity
>63.5 µM
Cytotoxic
50% cell death | >63.5 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins | Antimicrob Agents Chemother | 2008
Evidence 6 Activity

Activity

0.45±0.10
Toxicity
175 µg/mL
Hemolytic Cytotoxic
0.45±0.10 | 175 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The Naturally Occurring Host Defense Peptide, LL-37, and Its Truncated Mimetics KE-18 and KR-12 Have Selected Biocidal and Antibiofilm Activities Against Candida albicans, Staphylococcus aureus, and Escherichia coli In vitro. | Front Microbiol | 2017
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
>80 µM
Hemolytic Cytotoxic
50% Hemolysis | >80 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Backbone Cyclization and Dimerization of LL-37-Derived Peptides Enhance Antimicrobial Activity and Proteolytic Stability. | Front Microbiol | 2020
Evidence 8 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Mouse osteoblastic cells MC3T3-E1

Target

Mouse osteoblastic cells MC3T3-E1

Source & Reference

NA
DBAASP
Antibacterial and Anti-Inflammatory Properties of a Novel Antimicrobial Peptide Derived from LL-37. | Antibiotics (Basel) | 2022
Evidence 9 Activity

Activity

0% Cytotoxicity
Toxicity
100 µg/mL
Cytotoxic
0% Cytotoxicity | 100 | µg/mL | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Dodecapeptides derived from human cathelicidin with potent activity against carbapenem-resistant Acinetobacter baumannii. | Eur J Med Chem | 2025
Evidence 10 Activity

Activity

0% Cytotoxicity
Toxicity
100 µg/mL
Cytotoxic
0% Cytotoxicity | 100 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Dodecapeptides derived from human cathelicidin with potent activity against carbapenem-resistant Acinetobacter baumannii. | Eur J Med Chem | 2025
Evidence 11 Activity

Activity

<1% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
<1% Hemolysis | 100 | µg/mL | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Dodecapeptides derived from human cathelicidin with potent activity against carbapenem-resistant Acinetobacter baumannii. | Eur J Med Chem | 2025
Evidence 12 Activity

Activity

0% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 13 Activity

Activity

IC50
Toxicity
84.20 µg/mL
Cytotoxic
IC50 | 84.20 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 14 Activity

Activity

10% Cytotoxicity
Toxicity
32 µg/mL
Cytotoxic
10% Cytotoxicity | 32 | µg/mL | target cell: Murine macrophage cells J774A.1

Target

Murine macrophage cells J774A.1

Source & Reference

NA
DBAASP
Antimicrobial Peptides with Enhanced Salt Resistance and Antiendotoxin Properties. | Int J Mol Sci | 2020
Evidence 15 Activity

Activity

60% Cytotoxicity
Toxicity
64 µg/mL
Cytotoxic
60% Cytotoxicity | 64 | µg/mL | target cell: Murine macrophage cells J774A.1

Target

Murine macrophage cells J774A.1

Source & Reference

NA
DBAASP
Antimicrobial Peptides with Enhanced Salt Resistance and Antiendotoxin Properties. | Int J Mol Sci | 2020
Evidence 16 Activity

Activity

0.6±0.2% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
0.6±0.2% Hemolysis | 256 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Discovery of novel antibacterial agent for the infected wound treatment: all-hydrocarbon stapling optimization of LL-37 | Theranostics | 2024
Evidence 17 Activity

Activity

IC50
Toxicity
>256 µg/mL
Cytotoxic
IC50 | >256 | µg/mL | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Discovery of novel antibacterial agent for the infected wound treatment: all-hydrocarbon stapling optimization of LL-37 | Theranostics | 2024
Evidence 18 Activity

Activity

IC50
Toxicity
38.73 µg/mL
Cytotoxic
IC50 | 38.73 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 19 Activity

Activity

5% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 20 Activity

Activity

IC50
Toxicity
10.13 µg/mL
Cytotoxic
IC50 | 10.13 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 21 Activity

Activity

0% Hemolysis
Toxicity
16 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 16 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 22 Activity

Activity

5% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 64 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 23 Activity

Activity

50% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 24 Activity

Activity

IC50
Toxicity
3.23 µg/mL
Cytotoxic
IC50 | 3.23 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 25 Activity

Activity

5% Hemolysis
Toxicity
4 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 4 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 26 Activity

Activity

50% Hemolysis
Toxicity
16 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 16 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 27 Activity

Activity

100% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 64 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 28 Activity

Activity

IC50
Toxicity
5.97 µg/mL
Cytotoxic
IC50 | 5.97 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 29 Activity

Activity

100% Hemolysis
Toxicity
128 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 128 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 30 Activity

Activity

IC50
Toxicity
7.60 µg/mL
Cytotoxic
IC50 | 7.60 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 31 Activity

Activity

IC50
Toxicity
1.29 µg/mL
Cytotoxic
IC50 | 1.29 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 32 Activity

Activity

<5% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
<5% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 33 Activity

Activity

IC50
Toxicity
40.50 µg/mL
Cytotoxic
IC50 | 40.50 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 34 Activity

Activity

5% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 35 Activity

Activity

35% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
35% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 36 Activity

Activity

IC50
Toxicity
10 µg/mL
Cytotoxic
IC50 | 10 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 37 Activity

Activity

50% Hemolysis
Toxicity
>800 µM
Hemolytic Cytotoxic
50% Hemolysis | >800 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short KR-12 analogs designed from human cathelicidin LL-37 possessing both antimicrobial and antiendotoxic activities without mammalian cell toxicity. | J Pept Sci | 2013
Evidence 38 Activity

Activity

EC50
Toxicity
0.8 µg/mL
Cytotoxic
EC50 | 0.8 | µg/mL | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
KR12 peptide associated with cyclodextrin: Antimicrobial and antitumor activities. | Biointerphases | 2016
Evidence 39 Activity

Activity

73% Hemolysis
Toxicity
125 µg/mL
Hemolytic Cytotoxic
73% Hemolysis | 125 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
KR12 peptide associated with cyclodextrin: Antimicrobial and antitumor activities. | Biointerphases | 2016
Evidence 40 Activity

Activity

10.6% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
10.6% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural location determines functional roles of the basic amino acids of KR-12, the smallest antimicrobial peptide from human cathelicidin LL-37. | RSC Adv | 2013
Evidence 41 Activity

Activity

IC50
Toxicity
74.60 µg/mL
Cytotoxic
IC50 | 74.60 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Lipidated Analogs of the LL-37-Derived Peptide Fragment KR12-Structural Analysis, Surface-Active Properties and Antimicrobial Activity. | Int J Mol Sci | 2020
Evidence 42 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.